ProCE Banner Activity

Practical Considerations for Using PARP Inhibitors in Ovarian Cancer: Key ESMO Congress Updates

Clinical Thought
Two expert gynecologic oncologists discuss how to optimally use PARP inhibitors to treat patients with ovarian cancer.

Released: October 19, 2022

Expiration: October 18, 2023

No longer available for credit.

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability, AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp and Dohme, Zentalis; researcher: Apmonia; AstraZeneca.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme, Novartis, Seagen, Sutro.